# Denali Therapeutics Inc. (DNLI) stock news and updates

As of November 5, 2026. Source: https://www.clearthesis.ai/updates/DNLI

## Our view on the Denali Therapeutics Inc. investment thesis

Full investment thesis: https://www.clearthesis.ai/thesis/DNLI

## Latest updates on Denali Therapeutics Inc.

### Avlayah sales reach $18 million as Denali swings to a profit

*November 5, 2026 · earnings · significance: major · signal: positive*

Denali reported its second full quarter of sales for Avlayah, its first approved drug for Hunter syndrome. Revenue reached nearly $18 million, and management expects that to nearly double next quarter. This growth is a critical test for the company's technology, which is designed to carry medicines across the blood-brain barrier, a protective layer that usually blocks drugs from reaching the brain. The company reported a profit of $70 million this quarter, though this was largely due to a one-time $194 million gain from selling a regulatory voucher. This sale helped Denali maintain a $1 billion cash cushion, which is vital for a biotech company that is still spending heavily to develop its next four drugs for rare brain diseases.

Sources: [8-K filing](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000107/0001714899-26-000107-index.htm)

### Avlayah named best biotechnology product of 2026

*November 5, 2026 · news · significance: minor · signal: positive*

The Galien Foundation, an organization that honors medical innovation, awarded Avlayah its top prize for biotechnology. The award highlights the drug's role as the first approved biologic designed to cross the blood-brain barrier. While such awards do not directly impact sales, they help validate Denali's delivery technology as it prepares to submit its second drug for approval next year.

Sources: [GlobeNewsWire](https://www.globenewswire.com/news-release/2026/10/30/3392265/0/en/denali-therapeutics-receives-2026-prix-galien-usa-award-for-avlayah-tividenofusp-alfa-eknm-as-best-biotechnology-product.html)

## Denali Therapeutics Inc. earnings

In Q3 2026, reported on November 3, 2026, Denali Therapeutics Inc. posted earnings of $0.37 per share against $-0.27 expected, and revenue of $17.8 million against $12.7 million expected.

The next earnings report is expected on February 25, 2027. Analysts expect $-0.64 per share. Revenue is expected around $32.3 million.

What to watch: Avlayah sales, which need to keep climbing to prove the company's delivery technology can build a profitable business.

## Recent analyst activity on DNLI

- November 4, 2026: Wedbush Kept rating at Outperform.
- November 4, 2026: BTIG Kept rating at Buy.
- November 4, 2026: Morgan Stanley Kept rating at Overweight.

## What's ahead for Denali Therapeutics Inc.

- February 25, 2027: Earnings report — The company shows how it did over the last three months. The most important update for the stock.

---

Published by Clearthesis (https://www.clearthesis.ai). Informational only, not investment advice.
Full page: https://www.clearthesis.ai/updates/DNLI
